Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lymphoid Cells and Tissues

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...

Primary Lymphoid Organs

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

Secondary Lymphoid Organs

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

PREDICT-GTN 2: Two-factor streamlined models match FIGO performance in gestational trophoblastic neoplasia.

Gynecologic oncology·2023

Same author

Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia.

Gynecologic oncology·2022

Same author

PREDICT-GTN 1: Can we improve the FIGO scoring system in gestational trophoblastic neoplasia?

International journal of cancer·2022

Same author

Computed tomography chest imaging offers no advantage over chest X-ray in the initial assessment of gestational trophoblastic neoplasia.

British journal of cancer·2020

Same author

M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia.

International journal of cancer·2020

Same author

Placental site trophoblastic tumour and epithelioid trophoblastic tumour.

Best practice & research. Clinical obstetrics & gynaecology·2020

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

Non-Hodgkin lymphoma.

Linda S Evans¹, Barry W Hancock

¹Weston Park Hospital, S10 2SJ, Sheffield, UK.

Lancet (London, England)

|July 18, 2003

Summary

Non-Hodgkin lymphoma encompasses diverse malignant diseases. Advances in molecular biology, classification, and treatments like chemotherapy and monoclonal antibodies are improving prognosis for adult lymphomas.

Area of Science:

Oncology
Hematology
Molecular Biology

Background:

Non-Hodgkin lymphoma is a broad term for lymphoproliferative malignant diseases with varied clinical and histological features.
Diagnosis can be challenging, with approximately 25% of cases presenting extranodally, posing unique clinical problems.

Purpose of the Study:

To explore the molecular basis of adult lymphomas.
To discuss the development of a classification system informed by biological understanding.
To examine how refined prognostic factor groupings aid clinical management.

Main Methods:

Review of molecular underpinnings of lymphoma subtypes.
Analysis of evolving classification systems.
Evaluation of prognostic factors in clinical decision-making.

More Related Videos

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Related Experiment Videos

Last Updated: Jul 13, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Main Results:

Understanding molecular basis has led to improved classification of lymphoma subgroups.
Refined prognostic factor identification enhances clinical management strategies.
Chemotherapy has improved survival for aggressive lymphomas; novel therapies show promise for indolent and aggressive types.

Conclusions:

A biologically-based classification system is crucial for managing adult lymphomas.
Advances in chemotherapy and monoclonal antibody therapy are improving patient outcomes.
Continued research into molecular mechanisms and novel treatments will further enhance lymphoma prognosis.